Search
Nesbuvir
go.drugbank.com/drugs/DB07238InvestigationalNesbuvir has been investigated for the treatment of Hepatitis C.
Categories: Heterocyclic Compounds, 2-RingEmodin
go.drugbank.com/drugs/DB07715InvestigationalEmodin has been investigated for the treatment of Polycystic Kidney.
Synonyms: 1,3,8-trihydroxy-6-methyl-9,10-anthracenedione, 1,3,8-trihydroxy-6-methyl-9,10-anthraquinoneRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,
Categories: Vascular Endothelial Growth Factor Receptor 2 Antagonist, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: CYRAMZA®, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 1 ADETTazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalIt is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections.
Mixtures: ZERBAXA ® 1 G/0.5 G, ZERBAXA ® 1 G/0.5 GCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingEvening primrose oil
go.drugbank.com/drugs/DB11358ApprovedNutraceutical[A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". … Evening primrose oil comes from the extraction from _Oenothera biennis_ seeds and it is commonly used as an alternative source for omega-6 essential fatty acids.
Synonyms: Oenothera biennis l. oil, Oenothera lamarckiana l. oilMixtures: Hovid Omega-3 + 6, Kordel"s CoQ10 75MG + Omega 3-6 CapsulesAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.
Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody InteractionsProducts: TECENTRIQ®, TECENTRİQ 840MG/14 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETAlmasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer.
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. … [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.
Synonyms: 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazolineCategories: Adrenergic alpha-2 Receptor Agonists, Serotonin 5-HT2 Receptor AgonistsDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … therapy to diet and exercise in the management of 2 diabetes (T2DM).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLZidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription.
Mixtures: N/A, LAVUZID® NCategories: Cytochrome P-450 Substrates, P-glycoprotein substrates